OSR Holdings, Inc. is a global healthcare company, dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. The Company is focused on building and developing a portfolio of transformative therapies and healthcare solutions. The Company's operating businesses (through its three wholly owned subsidiaries) include developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases and neurovascular intervention medical device and systems distribution in Korea. The Company’s subsidiary, Vaximm’s flagship asset, VXM01, is a late clinical-stage (NCT037500701) immuno-oncology candidate for glioblastoma. Vaximm has three clinical and pre-clinical drug candidates targeting diseases ranging from glioblastoma to gastrointestinal stromal tumor to ocular diseases. The Company has operations in Europe and South Korea.
BörsenkürzelOSRH
Name des UnternehmensOSR Holdings Inc
IPO-datumFeb 10, 2023
CEOHwang (Kuk Hyoun)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 10
Addresse10900 Ne 4Th Street, Suite 2300
StadtBELLEVUE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl98004
Telefon14256357700
Websitehttps://osr-holdings.com/
BörsenkürzelOSRH
IPO-datumFeb 10, 2023
CEOHwang (Kuk Hyoun)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten